the invention relates to a chronic articular inflammation - modulating composition which uses collagen - polyvinylpyrrolidone . collagen turnover is modulated using collagen - pvp in patients with rheumatoid arthritis and osteoarthritis , since the biocomplex negatively regulates collagenolytic activity and increases the content of type iii collagen and timp - 1 to levels similar to those observed in normal synovia . in this way , the chronic inflammatory process is altered by the collagen - pvp , as described above , owing to the negative regulation of il - 1β , the tnf - α of il - 8 and the adhesion molecules , since said molecules can induce the expression and activation of collagenolytic enzymes , as well as the proliferation and migration of synovial cells by means of the adhesive mechanisms including the adhesion molecules , and the induction and activation of cox - 1 . in addition to cellular anchoring , the interaction of the extracellular matrix integrins generates signals which regulate the expression of m mps , suggesting that the adhesion molecules can also play a part in tissue destruction associated with rheumatoid arthritis . moreover , the decrease in the synthesis of tnf - α and il - 1β appears to stimulate the cell death of synoviocytes by means of apoptosis , which , in turn , seems to contribute to the inhibition of the proliferation of synovial cells , the formation of pannus and the destruction of the articular tissue .